Adrián Muñoz-Barrera

Dr. Adrián Muñoz-Barrera

Instituto Tecnológico y de Energías Renovables, Tenerife, Spain
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2022 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
JWJustin Wagner
Justin Wagner
NONathan Olson
Nathan Olson
LHLindsay Harris
Lindsay Harris
JMJennifer McDaniel
Jennifer McDaniel
HCHaoyu Cheng
Haoyu Cheng
FSFritz Sedlazeck
Fritz Sedlazeck

1 May 2023 in Emerging Microbes & Infections
Verified
Journal Article
Open access
LCLaura Ciuffreda
Laura Ciuffreda
JLJosé Miguel Lorenzo-Salazar
José Miguel Lorenzo-Salazar
DADiego García-Martínez de Artola
Diego García-Martínez de Artola
HGHelena Gil-Campesino
Helena Gil-Campesino
JAJulia Alcoba-Florez
Julia Alcoba-Florez
Carlos FloresCarlos Flores
Carlos Flores
The emergence of the Omicron SARS-CoV-2 variant of concern has changed the COVID-19 scenario as this variant is characterized by high transmissibility and immune evasion ability. To evaluate the impact of this variant on the Canary Islands (Spain) population, we determined the reinfection rates and disease severity associated with the Omicron sublineages and the previously circulating variants of concern. We performed a retrospective observational study on 21,745 SARS-CoV-2 viral genomes collected from December 2020 to July 2022 in the Canary Islands (Spain). We compared the reinfection rates between lineages using pairwise proportion and Fisher’s exact tests. To assess disease severity, we studied the association of Alpha, Delta, BA.1, BA.2, BA.5, and other risk factors on 28-day hospital mortality using logistic regression and Cox proportional hazard models. We observed 127 bona fide reinfection cases throughout the study period. We found that BA.5 had the highest reinfection rate compared to other lineages (vs. Delta p= 2.89 x 10-25; vs. BA.1 p= 5.17 x 10-11; vs. BA.2 p= 0.002). Among the 1,094 hospitalized patients, multivariate logistic regression showed that Alpha (Odds Ratio [OR]= 0.45, 95% Confidence Interval [CI]= 0.23-0.87, p= 0.02), BA.2 (OR= 0.37, 95% CI= 0.22-0.63, p= 1.91x10-4), and BA.5 (OR=0.30 95% CI= 0.16-0.55, p=1.05x10-4) had lower 28-day hospital mortality compared to Delta. These results were confirmed by using Cox proportional hazard models. Omicron lineages, and in particular BA.5, were associated with higher reinfection rates and lower disease severity (28-day hospital mortality) than previously circulating variants of concern.

Verified
Journal Article
Open access
PDF file
RRRomina Cabrera Rodríguez
Romina Cabrera Rodríguez
SPSilvia Pérez-Yanes
Silvia Pérez-Yanes
RGRafaela González-Montelongo
Rafaela González-Montelongo
JLJosé Miguel Lorenzo-Salazar
José Miguel Lorenzo-Salazar
JEJudith Estévez-Herrera
Judith Estévez-Herrera
Agustín Valenzuela-fernándezAgustín Valenzuela-fernández
Agustín Valenzuela-fernández
The transactive response DNA-binding protein (TARDBP/TDP-43) influences the processing of diverse transcripts, including that of histone deacetylase 6 (HDAC6). Here, we assessed TDP-43 activity in terms of regulating CD4+ T-cell permissivity to HIV-1 infection. We observed that overexpression of wt-TDP-43 increased both mRNA and protein levels of HDAC6, resulting in impaired HIV-1 infection independently of the viral envelope glycoprotein complex (Env) tropism. Consistently, using an HIV-1 Env-mediated cell-to-cell fusion model, the overexpression of TDP-43 levels negatively affected viral Env fusion capacity. Silencing of endogenous TDP-43 significantly decreased HDAC6 levels and increased the fusogenic and infection activities of the HIV-1 Env. Using pseudovirus bearing primary viral Envs from HIV-1 individuals, overexpression of wt-TDP-43 strongly reduced the infection activity of Envs from viremic non-progressors (VNP) and rapid progressors (RP) patients down to the levels of the inefficient HIV-1 Envs observed in long-term non-progressor elite controllers (LTNP-EC). On the contrary, silencing endogenous TDP-43 significantly favored the infectivity of primary Envs from VNP and RP individuals, and notably increased the infection of those from LTNP-EC. Taken together, our results indicate that TDP-43 shapes cell permissivity to HIV-1 infection, affecting viral Env fusion and infection capacities by altering the HDAC6 levels and associated tubulin-deacetylase anti-HIV-1 activity.

13 November 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AUAna Díaz-de Usera
Ana Díaz-de Usera
JLJosé Miguel Lorenzo-Salazar
José Miguel Lorenzo-Salazar
LRLuis Alberto Rubio-Rodríguez
Luis Alberto Rubio-Rodríguez
AMAdrián Muñoz-Barrera
Adrián Muñoz-Barrera
BGBeatriz Guillen-Guio
Beatriz Guillen-Guio
Carlos FloresCarlos Flores
Carlos Flores
Whole-exome sequencing has become a popular technique in research and clinical settings, assisting in disease diagnosis and increasing the understanding of disease pathogenesis. In this study, we aimed to compare common enrichment capture solutions available in the market. Peripheral blood-purified DNA samples were enriched with SureSelectQXT V6 (Agilent) and various Illumina solutions: TruSeq DNA Nano, TruSeq DNA Exome, Nextera DNA Exome, and Illumina DNA Prep with Enrichment, and sequenced on a HiSeq 4000. We found that their percentage of duplicate reads was as much as 2 times higher than previously reported values for the previous HiSeq series. SureSelectQXT and Illumina DNA Prep with Enrichment showed the best average on-target coverage, which improved when off-target regions were included. At high coverage levels and in shared bases, these two solutions and TruSeq DNA Exome provided three of the best performances. With respect to the number of small variants detected, SureSelectQXT presented the lowest number of detected variants in target regions. When off-target regions were considered, its ability equalized to other solutions. Our results show SureSelectQXT and Illumina DNA Prep with Enrichment to be the best enrichment capture solutions.

8 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
JWJustin Wagner
Justin Wagner
NONathan Olson
Nathan Olson
JMJennifer McDaniel
Jennifer McDaniel
LHLindsay Harris
Lindsay Harris
BPBrendan J. Pinto
Brendan J. Pinto
JZJustin M. Zook
Justin M. Zook
The sex chromosomes contain complex, important genes impacting medical phenotypes, but differ from the autosomes in their ploidy and large repetitive regions. To enable technology developers along with research and clinical laboratories to evaluate variant detection on male sex chromosomes X and Y, we create a small variant benchmark set with 111,725 variants for the Genome in a Bottle HG002 reference material. We develop an active evaluation approach to demonstrate the benchmark set reliably identifies errors in challenging genomic regions and across short and long read callsets. We show how complete assemblies can expand benchmarks to difficult regions, but highlight remaining challenges benchmarking variants in long homopolymers and tandem repeats, complex gene conversions, copy number variable gene arrays, and human satellites.

9 October 2020 in Journal of Medical Internet Research
Verified
Journal Article
Open access
Alejandro Mendoza-AlvarezAlejandro Mendoza-Alvarez
Alejandro Mendoza-Alvarez
AMAdrián Muñoz-Barrera
Adrián Muñoz-Barrera
LRLuis Alberto Rubio-Rodríguez
Luis Alberto Rubio-Rodríguez
IMItahisa Marcelino-Rodríguez
Itahisa Marcelino-Rodríguez
ACAlmudena Corrales
Almudena Corrales
Carlos FloresCarlos Flores
Carlos Flores
Background: Hereditary angioedema is a rare genetic condition caused by C1 esterase inhibitor deficiency, dysfunction, or kinin cascade dysregulation, leading to an increased bradykinin plasma concentration. Hereditary angioedema is a poorly recognized clinical entity and is very often misdiagnosed as a histaminergic angioedema. Despite its genetic nature, first-line genetic screening is not integrated in routine diagnosis. Consequently, a delay in the diagnosis, and inaccurate or incomplete diagnosis and treatment of hereditary angioedema are common. Objective: In agreement with recent recommendations from the International Consensus on the Use of Genetics in the Management of Hereditary Angioedema, to facilitate the clinical diagnosis and adapt it to the paradigm of precision medicine and next-generation sequencing–based genetic tests, we aimed to develop a genetic annotation tool, termed Hereditary Angioedema Database Annotation (HADA). Methods: HADA is built on top of a database of known variants affecting function, including precomputed pathogenic assessment of each variant and a ranked classification according to the current guidelines from the American College of Medical Genetics and Genomics. Results: HADA is provided as a freely accessible, user-friendly web-based interface with versatility for the entry of genetic information. The underlying database can also be incorporated into automated command-line stand-alone annotation tools. Conclusions: HADA can achieve the rapid detection of variants affecting function for different hereditary angioedema types, and further integrates useful information to reduce the diagnosis odyssey and improve its delay.